Design Of Immunogens

$801,878ZIAFY2011AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 38873606 Paper 38773089 Paper 38704686 Paper 38430907 Paper 38177144 Paper 38170789 Paper 37605043 Paper 37554450 Paper 36629414 Paper 35783486 Paper 35537058 Paper 35319830 Paper 35115707 Paper 34461095 Paper 34315825 Paper 34135892 Paper 34020817 Paper 33826898 Paper 33803622 Paper 33803302 Paper 33554060 Paper 33494381 Paper 33453152 Paper 32755575 Paper 32676596 Paper 32443437 Paper 32295908 Paper 32294946 Paper 32080235 Paper 32045432 Paper 31371616 Paper 31348886 Paper 31004012 Paper 30995238 Paper 30943274 Paper 30876875 Paper 30420505 Paper 30403372 Paper 30395637 Paper 30355496 Paper 30076101 Paper 29902444 Paper 29867235 Paper 29768174 Paper 29642014 Paper 29451984 Paper 29281818 Paper 29212041 Paper 29073183 Paper 29069295 Paper 29021918 Paper 28835504 Paper 28539444 Paper 28422787 Paper 28298421 Paper 28275193 Paper 28159876 Paper 27583777 Paper 27581977 Paper 27478931 Paper 27463224 Paper 27247400 Paper 26689967 Paper 26301691 Paper 26218507 Paper 26157122 Paper 26098893 Paper 26098315 Paper 25740988 Paper 25420104 Paper 25296255 Paper 25253346 Paper 25065977 Paper 23924998 Paper 23831758 Paper 23710622 Paper 23707685 Paper 23618766 Paper 23236069 Paper 22789610 Paper 22403408 Paper 22301150 Paper 22229123 Paper 22021856 Paper 21893538 Paper 21753119 Paper 21613394 Paper 21549714 Paper 21525337 Paper 21297864 Paper 20876137 Paper 20800070 Paper 20660185 Paper 20471426 Paper 20089638 Paper 19478876 Paper 19264769 Paper 19004960 Paper 17360741 Paper 16497577

Abstract

Based on our understanding of envelope-based mechanisms of humoral evasion, we have attempted to design envelope-based immunogens with these mechanisms disabled. Such modied immunogens with weakened defenses may elicit more broadly neutralizing antibodies. We have also devised scaffolding technologies, as a means of presenting structural mimics of the epitopes of broadly neutralizing antibodies to assist in their re-elicitation. Scaffolds can be non-homologous proteins, identified through searches of the entire protein data bank. Alternatively, scaffolds can be homologous proteins, which are structurally similar, but antigenically distinct from the HIV-1 envelope glycoproteins. An alternative to scaffolding involves "resurfacing", where the surface of a molecule, not involved in eliciting a desired response, is altered between "prime" and "boost" phases of immunization. Finally we have investigated both molecular motion and expression-system-dependent modulation of HIV-1 envelope antigenicity and immunogenicity.

View original record on NIH RePORTER →